Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
55–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Present with mild AD dementia based on the National Institute on Aging (NIA) and the Alzheimer's Association (AA) disease diagnostic criteria as determined by a qualified clinician approved by the Sponsor or designee.
Mini-Mental State Examination score of 20 to 26 inclusive at screening visit.
Has a florbetapir PET scan consistent with the presence of amyloid pathology at screening.
You may not be if
Significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).
Ocular pathology that significantly limits ability to reliably evaluate vision or the retina.
Use of strong inducers of cytochrome P450 3A (CYP3A).
Sensitivity to florbetapir or ¹⁸F-AV-1451.
Contraindication to MRI or PET or poor venous access for blood draws.
Clareo Health | A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
